128 related articles for article (PubMed ID: 36321470)
1. On the use of extreme value tail modeling for generalized pairwise comparisons with censored outcomes.
De Backer M; Legrand C; Péron J; Lambert A; Buyse M
Pharm Stat; 2023 Mar; 22(2):284-299. PubMed ID: 36321470
[TBL] [Abstract][Full Text] [Related]
2. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE-type marginal model for binary outcomes.
Westgate PM
Clin Trials; 2019 Feb; 16(1):41-51. PubMed ID: 30295512
[TBL] [Abstract][Full Text] [Related]
5. Generalized pairwise comparisons for censored data: An overview.
Deltuvaite-Thomas V; Verbeeck J; Burzykowski T; Buyse M; Tournigand C; Molenberghs G; Thas O
Biom J; 2023 Feb; 65(2):e2100354. PubMed ID: 36127290
[TBL] [Abstract][Full Text] [Related]
6. An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.
Péron J; Buyse M; Ozenne B; Roche L; Roy P
Stat Methods Med Res; 2018 Apr; 27(4):1230-1239. PubMed ID: 27487842
[TBL] [Abstract][Full Text] [Related]
7. Correcting the bias of the net benefit estimator due to right-censored observations.
Péron J; Idlhaj M; Maucort-Boulch D; Giai J; Roy P; Collette L; Buyse M; Ozenne B
Biom J; 2021 Apr; 63(4):893-906. PubMed ID: 33615533
[TBL] [Abstract][Full Text] [Related]
8. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
9. A simple hybrid variance estimator for the Kaplan-Meier survival function.
Borkowf CB
Stat Med; 2005 Mar; 24(6):827-51. PubMed ID: 15558837
[TBL] [Abstract][Full Text] [Related]
10. Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies.
Wang X; Bai F; Pang H; George SL
J Biopharm Stat; 2019; 29(4):592-605. PubMed ID: 31286838
[TBL] [Abstract][Full Text] [Related]
11. Restricted Net Treatment Benefit in oncology.
Piffoux M; Ozenne B; De Backer M; Buyse M; Chiem JC; Péron J
J Clin Epidemiol; 2024 Jun; 170():111340. PubMed ID: 38570079
[TBL] [Abstract][Full Text] [Related]
12. A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.
Cantagallo E; De Backer M; Kicinski M; Ozenne B; Collette L; Legrand C; Buyse M; Péron J
Biom J; 2021 Feb; 63(2):272-288. PubMed ID: 32939818
[TBL] [Abstract][Full Text] [Related]
13. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
14. Survivor function estimators under group sequential monitoring based on the logrank statistic.
Gorfine M
Lifetime Data Anal; 2003 Jun; 9(2):175-93. PubMed ID: 12735495
[TBL] [Abstract][Full Text] [Related]
15. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
Lu QS; Chow SC; Tse SK
J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
[TBL] [Abstract][Full Text] [Related]
16. Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail.
Gong Q; Fang L
Pharm Stat; 2012; 11(2):135-40. PubMed ID: 22323424
[TBL] [Abstract][Full Text] [Related]
17. Some insight on censored cost estimators.
Zhao H; Cheng Y; Bang H
Stat Med; 2011 Aug; 30(19):2381-8. PubMed ID: 21748774
[TBL] [Abstract][Full Text] [Related]
18. Alternatives to the Kaplan-Meier estimator of progression-free survival.
Zhang JJ; Sun Z; Yuan H; Wang M
Int J Biostat; 2020 Sep; 17(1):99-115. PubMed ID: 32892174
[TBL] [Abstract][Full Text] [Related]
19. Summarising censored survival data using the mean residual life function.
Alvarez-Iglesias A; Newell J; Scarrott C; Hinde J
Stat Med; 2015 May; 34(11):1965-76. PubMed ID: 25628067
[TBL] [Abstract][Full Text] [Related]
20. Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study.
Giai J; Maucort-Boulch D; Ozenne B; Chiêm JC; Buyse M; Péron J
Stat Med; 2021 Feb; 40(3):553-565. PubMed ID: 33140505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
